View in EDS

Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069.

Saved in:
Bibliographic Details
Title: Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069.
Authors: Orsi DL; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Pook E; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Bräuer N; Nuvisan ICB GmbH, 13353 Berlin, Germany., Friberg A; Nuvisan ICB GmbH, 13353 Berlin, Germany., Lienau P; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Lemke CT; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Stellfeld T; Nuvisan ICB GmbH, 13353 Berlin, Germany., Brüggemeier U; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Pütter V; Nuvisan ICB GmbH, 13353 Berlin, Germany., Meyer H; Nuvisan ICB GmbH, 13353 Berlin, Germany., Baco M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Tang S; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Cherniack AD; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States., Westlake L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Bender SA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Kocak M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Strathdee CA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Meyerson M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts 02115, United States., Eis K; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Goldstein JT; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Source: Journal of medicinal chemistry [J Med Chem] 2022 Nov 10; Vol. 65 (21), pp. 14843-14863. Date of Electronic Publication: 2022 Oct 21.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.2c01379